2024: UPS, the juicy 5%-yielding loser, waiting for the FedEx spin
Value delivery on the radar
FDX: WAITING FOR THE SPINHON: BREAK-UP ALLUREDSV: BREACHING SUPPORTVW: BOLT-ON DEALAMZN: TOP PICK DHL: STRONGER TIESXPO: TOP PICKDHL: HIT HARDWMT: NEW CHINESE TIESKNIN: NEW LOWS TSLA: EUPHORIAXPO: RECORDTFII: PAYOUT UPDATER: TOP MANAGEMENT UPDATE
FDX: WAITING FOR THE SPINHON: BREAK-UP ALLUREDSV: BREACHING SUPPORTVW: BOLT-ON DEALAMZN: TOP PICK DHL: STRONGER TIESXPO: TOP PICKDHL: HIT HARDWMT: NEW CHINESE TIESKNIN: NEW LOWS TSLA: EUPHORIAXPO: RECORDTFII: PAYOUT UPDATER: TOP MANAGEMENT UPDATE
THE WALL STREET JOURNAL reports:
Johnson & Johnson is poised to begin a roadshow to pitch shares of its consumer-healthcare business, the producer of household names such as Tylenol, in a test for an IPO market that has been in the doldrums for the past year.
Kenvue Inc. plans to start meeting with prospective investors as early as Monday, people familiar with the matter said. The goal is to raise $3.5 billion or more in the offering at a valuation close to $40 billion, the people said. IPO roadshows typically last anywhere from a few days to a week ahead of the stock’s trading debut…
The full post is here.
Comment on this article